A Prospective Cohort Study of Advanced Colorectal Cancer Treated With Oxaliplatin and Irinotecan.
NCT05731336 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2023-02-16
Summary
The goal of this prospective observational study is to learn about the treatment decisions in advanced colorectal cancer treated with oxaliplatin and irinotecan. The main questions:1. learn about the efficacy and safety of immunotherapy or targeted drugs or other chemotherapy for patients treated with oxaliplatin and irinotecan(non-retreatment/rechallenge group,NR group). 2. learn about the efficacy and safety of oxaliplatin or irinotecan for patients treated with oxaliplatin and irinotecan (retreatment/rechallenge group, RT/RC group). 3. compare the efficacy and safety of various treatment regimens for patients treated with oxaliplatin and irinotecan. This study will only collect the clinical data of patients, without any intervention, in the treatment services. All participants will be provided written informed consent as per the Declaration of Helsinki principles.
Conditions
- Advanced Colorectal Cancer
Sponsors & Collaborators
-
Sun Yat-sen University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-05-01
- Primary Completion
- 2025-05-31
- Completion
- 2026-05-31
Countries
- China
Study Locations
More Related Trials
-
Neoadjuvant Therapy (NALIRIFOX) for Locally Advanced Colon and Upper Rectal Cancer
NCT07020468 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Oxaliplatin Adjuvant Chemotherapy After Curative Resection of Primary Colon Cancer
NCT04416490 ·Status: ACTIVE_NOT_RECRUITING
-
Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
NCT05799443 ·Status: UNKNOWN ·Phase: PHASE2
-
Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients
NCT05797467 ·Status: RECRUITING ·Phase: PHASE3
-
Predictive Factors for Outcomes of Fruquintinib Plus Immunotherapy in Colorectal Cancer
NCT05635149 ·Status: UNKNOWN
-
Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT
NCT05763927 ·Status: UNKNOWN ·Phase: PHASE2
-
Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer
NCT07059338 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer
NCT06764680 ·Status: RECRUITING ·Phase: PHASE2
-
Neoadjuvant Therapy for Locally Advanced Rectal Cancer
NCT06853769 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.
NCT07343791 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer
NCT04304209 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
The Culture of Advanced/Recurrent/Metastatic Colorectal Cancer Organoids and Drug Screening
NCT05304741 ·Status: UNKNOWN
-
A Study of Combination of Anti-PD1 Antibody-activated TILs and Chemotherapy in Colorectal Cancer
NCT03904537 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer
NCT03484221 ·Status: UNKNOWN ·Phase: PHASE2
-
Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases
NCT05353582 ·Status: UNKNOWN ·Phase: PHASE2
-
PTC Drug Sensitivity Detection to Guide Postoperative Adjuvant of Colorectal Cancer
NCT05978349 ·Status: UNKNOWN ·Phase: NA
-
Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.
NCT06778382 ·Status: RECRUITING ·Phase: PHASE2
-
Neoadjuvant Treatment of Fruquintinib Combined With Concurrent Chemoradiotherapy for LARC
NCT05575635 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Radical Concurrent Chemoradiotherapy With DDP/5-FU and PD-1 Antibody for Non-metastatic Rectal Squamous Cell Carcinoma
NCT06364384 ·Status: RECRUITING ·Phase: PHASE2
-
Total Neoadjuvant Therapy With PD-1 for Locally Advcancer Rectal Cancer
NCT07214142 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
PET-CT and Circulating Tumor Cells in Colorectal Cancer
NCT01163305 ·Status: COMPLETED
-
Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
NCT02031939 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study
NCT05998122 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
An Exploratory Study of Sequential Transarterial Chemoembolization With Lipiodol and Neoadjuvant Chemotherapy in the Treatment of Initial Unresectable Colorectal Cancer (CRC)
NCT05340231 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Preoperative (Chemo)Radiotherapy for Locally Recurrent Rectal Cancer
NCT06617052 ·Status: NOT_YET_RECRUITING